Let's change the story for people living with obesity. Join Obesity Therapy Area - Novo Nordisk

(1:30)

🎉 ¡Año Nuevo Chino! Ana retoma sus propósito y lo intenta de nuevo 🐉✨

(28)

🎉 ¡Año Nuevo Chino! Ana retoma sus propósito y lo intenta de nuevo 🐉✨

(1:14)

Join us for a career within Manufacturing

(1:42)

Join us for a career within Engineering

(1:59)

Meet Brittany, Engineering a Rewarding Career in Manufacturing

(1:25)

Meet Charlene, Leaders on the Line in U.S. Manufacturing

(1:12)

Meet Matt, Military Veteran Turned Logistics Leader

(1:24)

Join us for a career within Supply Chain

(1:59)

Join us for a career within Project Management

(2:10)

Is Novo Nordisk Stock a Buy Now?

(8:7)

Wegovy sales double, but Novo Nordisk expects slower growth in 2025 | REUTERS

(1:16)

Novo Nordisk CEO Lars Fruergaard Jørgensen on Q4 results, Wegovy demand and drug pipeline outlook

(7:56)

How to use NovoPen 4

(6:46)

Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly

(3:58)

The spirit of our founders: The values and mindsets that created Novo Nordisk a century ago

(24:15)

Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging

(4:8)

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company

(19:20)

Novo Nordisk (Ozempic)

(3:45:26)

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz

(2:53)

How Novo Nordisk built an empire selling diabetes and weight-loss drugs

(2:16)

How a new Denmark tariff could impact Novo Nordisk

(2:49)

Novo Nordisk Selloff Is an Overreaction, Barclays' Field Says

(4:35)

Novo Nordisk plunges after obesity drug trial disappoints | REUTERS

(1:31)

Novo Nordisk CEO expects same growth for 2025

(3:1econd)

Novo Nordisk CEO testifies before Senate on weight loss drug prices

(1:55)

Join us in Novo Nordisk Manufacturing

(1:29)

BMO’s Evan David Seigerman cuts Novo Nordisk price target after Cagrisema data disappoints

(4:1econd)